AVEO Pharmaceuticals Stock Forecast, Price & News

-0.13 (-2.46 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume251,741 shs
Average Volume1.43 million shs
Market Capitalization$176.96 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Pharmaceuticals logo

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.84 out of 5 stars

Medical Sector

476th out of 2,214 stocks

Pharmaceutical Preparations Industry

234th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

Is AVEO Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVEO Pharmaceuticals stock.
View analyst ratings for AVEO Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than AVEO Pharmaceuticals?

Wall Street analysts have given AVEO Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AVEO Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,900,000 shares, a decline of 21.5% from the June 15th total of 2,420,000 shares. Based on an average trading volume of 625,400 shares, the short-interest ratio is currently 3.0 days. Approximately 6.3% of the company's shares are short sold.
View AVEO Pharmaceuticals' Short Interest

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for AVEO Pharmaceuticals

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.26. The biopharmaceutical company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $1.35 million. AVEO Pharmaceuticals had a negative net margin of 689.38% and a negative trailing twelve-month return on equity of 95.76%.
View AVEO Pharmaceuticals' earnings history

How has AVEO Pharmaceuticals' stock been impacted by Coronavirus?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AVEO shares have increased by 47.6% and is now trading at $5.15.
View which stocks have been most impacted by COVID-19

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals shares reverse split on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

4 brokerages have issued twelve-month price targets for AVEO Pharmaceuticals' stock. Their forecasts range from $9.00 to $26.00. On average, they expect AVEO Pharmaceuticals' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 249.5% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 56, Pay $1.08M)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 61, Pay $700.11k)
  • Mr. Erick Lucera CPA, CFA, Chief Financial Officer (Age 53)
  • Ms. Lisa M. Bruneau, VP of Financial Accounting & Reporting and Treasurer (Age 54)
  • Dr. Emile Farhan, Sr. VP of Technical Operations & Quality Assurance
  • Ms. Danielle Holland, Sr. Corp. Counsel & Corp. Sec.
  • Ms. Stefanie Solomon, Head of Compliance
  • Mr. Kevin Peacock, VP of Marketing
  • Mr. David Crist, VP of Sales
  • Ms. Catherine DeRose, VP of HR

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals CEO Tuan Ha-Ngoc on Tuan Ha-Ngoc has an approval rating of 61% among AVEO Pharmaceuticals' employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $5.15.

How much money does AVEO Pharmaceuticals make?

AVEO Pharmaceuticals has a market capitalization of $176.96 million and generates $6.02 million in revenue each year. The biopharmaceutical company earns $-35,580,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How many employees does AVEO Pharmaceuticals have?

AVEO Pharmaceuticals employs 49 workers across the globe.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is

Where are AVEO Pharmaceuticals' headquarters?

AVEO Pharmaceuticals is headquartered at 30 WINTER STREET, BOSTON MA, 02108.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 857-400-0101 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.